Inozyme Pharma Stock In The News

INZY Stock  USD 1.00  0.08  7.41%   
Our overall analysis of Inozyme Pharma's news coverage and content from conventional and social sources shows investors' bearish mood towards Inozyme Pharma. The specific impact of Inozyme Pharma news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Inozyme Pharma's overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Inozyme Pharma headlines in addition to utilizing other, more conventional financial analysis modules. Check out Inozyme Pharma Backtesting and Inozyme Pharma Hype Analysis.
For more information on how to buy Inozyme Stock please use our How to Invest in Inozyme Pharma guide.

Inozyme Pharma Today Top News and Investor Outlook

Macroaxis News: globenewswire.com
Inozyme Pharma Reports Full Year 2024 Fi...
https://www.globenewswire.com/news-release/2025/03/10/3039719/0/en/Inozyme-Pharma-Reports-Full-Year-2024-Financial-Results-and-Announces-Strategic-Prioritization-of-ENPP1-Deficiency-Pivotal-Program-and-Recent-Business-Highlights.html
 Neutral
Macroaxis News: globenewswire.com
Inozyme Pharma to Present Recently Annou...
https://www.globenewswire.com/news-release/2025/02/21/3030451/0/en/Inozyme-Pharma-to-Present-Recently-Announced-Interim-Data-for-INZ-701-in-Infants-and-Young-Children-with-ENPP1-Deficiency-at-CHOP-Cardiology-2025.html
 Neutral
Investors Business Daily at Macroaxis
Institutional investors own a significant stake of 45% in Inozyme Pharma, Inc. (NASDAQ:INZY)
https://finance.yahoo.com/news/institutional-investors-own-significant-stake-131017587.html
 Bullish
Yahoo News
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
https://finance.yahoo.com/news/inozyme-pharma-reports-inducement-grants-133000803.html
 Bullish
Macroaxis News: globenewswire.com
Inozyme Pharma to Participate in Upcoming Investor Conferences
https://www.globenewswire.com/news-release/2023/11/09/2777359/0/en/Inozyme-Pharma-to-Participate-in-Upcoming-Investor-Conferences.html
 Neutral
Yahoo News
Inozyme Pharma to Participate in Upcoming Investor Conferences
https://finance.yahoo.com/news/inozyme-pharma-participate-upcoming-investor-133000091.html
 Neutral
Macroaxis News: globenewswire.com
Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights
https://www.globenewswire.com/news-release/2023/11/07/2775119/0/en/Inozyme-Pharma-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Business-Highlights.html
 Neutral
Yahoo News
Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights
https://finance.yahoo.com/news/inozyme-pharma-reports-third-quarter-133000479.html
 Neutral
Macroaxis News: globenewswire.com
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
https://www.globenewswire.com/news-release/2023/11/03/2773445/0/en/Inozyme-Pharma-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
 Bullish
Yahoo News
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
https://finance.yahoo.com/news/inozyme-pharma-reports-inducement-grants-201500105.html
 Bullish

Inozyme Pharma Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Inozyme and other traded companies coverage with news coverage. We help investors stay connected with Inozyme headlines for the 15th of March 2025 to make an informed investment decision based on correlating the impacts of news items on Inozyme Stock performance. Please note that trading solely based on the Inozyme Pharma hype is not for everyone as timely availability and quick action are needed to avoid losses.
Inozyme Pharma's linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Inozyme Pharma investors visualize upcoming and past events in order to time the market based on Inozyme Pharma noise-free hype analysis.
Inozyme Pharma stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Inozyme earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Inozyme Pharma that are available to investors today. That information is available publicly through Inozyme media outlets and privately through word of mouth or via Inozyme internal channels. However, regardless of the origin, that massive amount of Inozyme data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Inozyme Pharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Inozyme Pharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Inozyme Pharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Inozyme Pharma alpha.

Inozyme Largest EPS Surprises

Earnings surprises can significantly impact Inozyme Pharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2025-03-10
2024-12-31-0.3733-0.42-0.046712 
2024-11-05
2024-09-30-0.44-0.390.0511 
2024-08-06
2024-06-30-0.39-0.44-0.0512 
2023-05-09
2023-03-31-0.45-0.40.0511 
2022-11-10
2022-09-30-0.43-0.380.0511 
2021-05-12
2021-03-31-0.54-0.470.0712 
View All Earnings Estimates

Inozyme Pharma Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Inozyme Pharma Stock. Current markets are strongly bullish. About 93% of major world exchanges and indexes are currently up. See today's market update for more information.
news
13th of March 2025
Q1 Earnings Estimate for Inozyme Pharma Issued By Wedbush
at thelincolnianonline.com 
Google News at Macroaxis
7th of March 2025
Inozyme Pharma Inc expected to post a loss of 41 cents a share - Earnings Preview - Tradin...
at news.google.com 
Gurufocus Stories at Macroaxis
21st of February 2025
Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young...
at gurufocus.com 
Macroaxis News
27th of January 2025
Disposition of 25000 shares by Douglas Treco of Inozyme Pharma subject to Rule 16b-3
at MacroaxisInsider 
news
15th of January 2025
HC Wainwright Predicts Inozyme Pharma Q1 Earnings
at thelincolnianonline.com 
Yahoo News
10th of January 2025
Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children w...
at finance.yahoo.com 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Inozyme Pharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Inozyme Pharma's short interest history, or implied volatility extrapolated from Inozyme Pharma options trading.

Additional Tools for Inozyme Stock Analysis

When running Inozyme Pharma's price analysis, check to measure Inozyme Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inozyme Pharma is operating at the current time. Most of Inozyme Pharma's value examination focuses on studying past and present price action to predict the probability of Inozyme Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inozyme Pharma's price. Additionally, you may evaluate how the addition of Inozyme Pharma to your portfolios can decrease your overall portfolio volatility.